Is the DEA's Response to Rescheduling Cannabis Overly Hyped? Calyx Responds

The Drug Enforcement Administration's consideration of rescheduling marijuana marks a significant shift in U.S. drug policy. Previously classified as Schedule I - alongside heroin and LSD - marijuana was deemed to lack medical value and carry high abuse potential. A comprehensive review by the Department of Health and Human Services highlighted marijuana's accepted medical applications and lower abuse potential, proposing reclassification to Schedule III, which includes ketamine and certain anabolic steroids.

Financial Opportunities for Cannabis Businesses

Cannabis businesses currently cannot deduct ordinary business expenses under IRS Code 280E due to Schedule I classification. Schedule III reclassification would allow these deductions, substantially reducing tax burdens and improving operational sustainability.

The Rescheduling Timeline: Slower Than You Think

The rescheduling process involves multiple stages: White House Office of Management and Budget review, public comment periods lasting several months, DEA feedback integration, and Federal Register publication. This extended timeline means implementation occurs gradually rather than immediately.

How the IRS Will Respond

Following Federal Register publication, the IRS will issue new guidelines and update forms to accommodate marijuana's reclassification. These adjustments require several months for implementation but will not apply retroactively to previous tax years.

Why You Must Act Now

Cannabis businesses should consider filing protective claims for refund to preserve amendment rights based on future legal changes. Trulieve has already secured $113 million in refunds from amended returns. Meticulous record-keeping and proactive IRS engagement strategies emphasizing sound legal arguments and compliance are essential for every operator in the space.